Efficacy and tolerability of formoterol Turbuhaler in children

A. Von Berg, S. F. Papageorgiou, S. Wille, T. Carrillo, C. Kattamis, Peter Joseph Benedict Helms

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A randomised, double-blind trial was undertaken to investigate the efficacy and tolerability of-formoterol Turbuhaler(R) in children with mild to moderate asthma. After a two-week run-in, 248 children aged 6-17 years were randomised to receive formoterol 4.5 and 9 mug b.i.d. or placebo for 12 weeks. Morning PEF (primary variable), was significantly improved versus placebo only in the formoterol 9 mug b.i.d. group (13 l/min, 95% CI: 1.9, 24.2%; p = 0.02). Both formoterol 4.5 and 9 mug significantly increased the pre-bronchodilator FEV, by 5.2-6.7% (p < 0.05) and reduced use of daytime relief medication versus placebo (p < 0.05). Formoterol 9 mug significantly reduced night-time reliever use and awakenings due to asthma versus placebo (p < 0.05). Both doses of formoterol were as well tolerated as placebo. In conclusion, formoterol 4.5 and 9 &mu;g b.i.d. is effective and well tolerated as maintenance therapy in children with mild to moderate asthma.

Original languageEnglish
Pages (from-to)852-856
Number of pages4
JournalInternational Journal of Clinical Practice
Volume57
Issue number10
Publication statusPublished - 2003

Keywords

  • ASTHMATIC-CHILDREN
  • PERSISTENT ASTHMA
  • INHALED CORTICOSTEROIDS
  • SALMETEROL XINAFOATE
  • SYMPTOMATIC ASTHMA
  • BUDESONIDE
  • ADOLESCENTS
  • SALBUTAMOL
  • POWDER
  • ONSET

Cite this

Von Berg, A., Papageorgiou, S. F., Wille, S., Carrillo, T., Kattamis, C., & Helms, P. J. B. (2003). Efficacy and tolerability of formoterol Turbuhaler in children. International Journal of Clinical Practice, 57(10), 852-856.

Efficacy and tolerability of formoterol Turbuhaler in children. / Von Berg, A.; Papageorgiou, S. F.; Wille, S.; Carrillo, T.; Kattamis, C.; Helms, Peter Joseph Benedict.

In: International Journal of Clinical Practice, Vol. 57, No. 10, 2003, p. 852-856.

Research output: Contribution to journalArticle

Von Berg, A, Papageorgiou, SF, Wille, S, Carrillo, T, Kattamis, C & Helms, PJB 2003, 'Efficacy and tolerability of formoterol Turbuhaler in children', International Journal of Clinical Practice, vol. 57, no. 10, pp. 852-856.
Von Berg A, Papageorgiou SF, Wille S, Carrillo T, Kattamis C, Helms PJB. Efficacy and tolerability of formoterol Turbuhaler in children. International Journal of Clinical Practice. 2003;57(10):852-856.
Von Berg, A. ; Papageorgiou, S. F. ; Wille, S. ; Carrillo, T. ; Kattamis, C. ; Helms, Peter Joseph Benedict. / Efficacy and tolerability of formoterol Turbuhaler in children. In: International Journal of Clinical Practice. 2003 ; Vol. 57, No. 10. pp. 852-856.
@article{8a8fdb9397534655a5e04b807e017474,
title = "Efficacy and tolerability of formoterol Turbuhaler in children",
abstract = "A randomised, double-blind trial was undertaken to investigate the efficacy and tolerability of-formoterol Turbuhaler(R) in children with mild to moderate asthma. After a two-week run-in, 248 children aged 6-17 years were randomised to receive formoterol 4.5 and 9 mug b.i.d. or placebo for 12 weeks. Morning PEF (primary variable), was significantly improved versus placebo only in the formoterol 9 mug b.i.d. group (13 l/min, 95{\%} CI: 1.9, 24.2{\%}; p = 0.02). Both formoterol 4.5 and 9 mug significantly increased the pre-bronchodilator FEV, by 5.2-6.7{\%} (p < 0.05) and reduced use of daytime relief medication versus placebo (p < 0.05). Formoterol 9 mug significantly reduced night-time reliever use and awakenings due to asthma versus placebo (p < 0.05). Both doses of formoterol were as well tolerated as placebo. In conclusion, formoterol 4.5 and 9 &mu;g b.i.d. is effective and well tolerated as maintenance therapy in children with mild to moderate asthma.",
keywords = "ASTHMATIC-CHILDREN, PERSISTENT ASTHMA, INHALED CORTICOSTEROIDS, SALMETEROL XINAFOATE, SYMPTOMATIC ASTHMA, BUDESONIDE, ADOLESCENTS, SALBUTAMOL, POWDER, ONSET",
author = "{Von Berg}, A. and Papageorgiou, {S. F.} and S. Wille and T. Carrillo and C. Kattamis and Helms, {Peter Joseph Benedict}",
year = "2003",
language = "English",
volume = "57",
pages = "852--856",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Efficacy and tolerability of formoterol Turbuhaler in children

AU - Von Berg, A.

AU - Papageorgiou, S. F.

AU - Wille, S.

AU - Carrillo, T.

AU - Kattamis, C.

AU - Helms, Peter Joseph Benedict

PY - 2003

Y1 - 2003

N2 - A randomised, double-blind trial was undertaken to investigate the efficacy and tolerability of-formoterol Turbuhaler(R) in children with mild to moderate asthma. After a two-week run-in, 248 children aged 6-17 years were randomised to receive formoterol 4.5 and 9 mug b.i.d. or placebo for 12 weeks. Morning PEF (primary variable), was significantly improved versus placebo only in the formoterol 9 mug b.i.d. group (13 l/min, 95% CI: 1.9, 24.2%; p = 0.02). Both formoterol 4.5 and 9 mug significantly increased the pre-bronchodilator FEV, by 5.2-6.7% (p < 0.05) and reduced use of daytime relief medication versus placebo (p < 0.05). Formoterol 9 mug significantly reduced night-time reliever use and awakenings due to asthma versus placebo (p < 0.05). Both doses of formoterol were as well tolerated as placebo. In conclusion, formoterol 4.5 and 9 &mu;g b.i.d. is effective and well tolerated as maintenance therapy in children with mild to moderate asthma.

AB - A randomised, double-blind trial was undertaken to investigate the efficacy and tolerability of-formoterol Turbuhaler(R) in children with mild to moderate asthma. After a two-week run-in, 248 children aged 6-17 years were randomised to receive formoterol 4.5 and 9 mug b.i.d. or placebo for 12 weeks. Morning PEF (primary variable), was significantly improved versus placebo only in the formoterol 9 mug b.i.d. group (13 l/min, 95% CI: 1.9, 24.2%; p = 0.02). Both formoterol 4.5 and 9 mug significantly increased the pre-bronchodilator FEV, by 5.2-6.7% (p < 0.05) and reduced use of daytime relief medication versus placebo (p < 0.05). Formoterol 9 mug significantly reduced night-time reliever use and awakenings due to asthma versus placebo (p < 0.05). Both doses of formoterol were as well tolerated as placebo. In conclusion, formoterol 4.5 and 9 &mu;g b.i.d. is effective and well tolerated as maintenance therapy in children with mild to moderate asthma.

KW - ASTHMATIC-CHILDREN

KW - PERSISTENT ASTHMA

KW - INHALED CORTICOSTEROIDS

KW - SALMETEROL XINAFOATE

KW - SYMPTOMATIC ASTHMA

KW - BUDESONIDE

KW - ADOLESCENTS

KW - SALBUTAMOL

KW - POWDER

KW - ONSET

M3 - Article

VL - 57

SP - 852

EP - 856

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 10

ER -